RU2575796C1 - Пегилированный конъюгат варианта рекомбинантного консенсусного интерферона и способ его получения, и применение - Google Patents

Пегилированный конъюгат варианта рекомбинантного консенсусного интерферона и способ его получения, и применение

Info

Publication number
RU2575796C1
RU2575796C1 RU2013119183/10A RU2013119183A RU2575796C1 RU 2575796 C1 RU2575796 C1 RU 2575796C1 RU 2013119183/10 A RU2013119183/10 A RU 2013119183/10A RU 2013119183 A RU2013119183 A RU 2013119183A RU 2575796 C1 RU2575796 C1 RU 2575796C1
Authority
RU
Russia
Prior art keywords
version
conjugate
interferon
consensus interferon
recombinant consensus
Prior art date
Application number
RU2013119183/10A
Other languages
English (en)
Other versions
RU2013119183A (ru
RU2575796C9 (ru
RU2575796C2 (ru
Inventor
Кай ФАНЬ
Хуа ЛО
Цзилань ЧЖАН
Сян Ли
И Чжан
Original Assignee
Бэйцзин Кавин Текнолоджи Шеар-Холдинг Ко., Лтд.
Чунцин Фагэнь Биомедикал Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бэйцзин Кавин Текнолоджи Шеар-Холдинг Ко., Лтд., Чунцин Фагэнь Биомедикал Инк. filed Critical Бэйцзин Кавин Текнолоджи Шеар-Холдинг Ко., Лтд.
Publication of RU2013119183A publication Critical patent/RU2013119183A/ru
Application granted granted Critical
Publication of RU2575796C2 publication Critical patent/RU2575796C2/ru
Publication of RU2575796C1 publication Critical patent/RU2575796C1/ru
Publication of RU2575796C9 publication Critical patent/RU2575796C9/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение относится к области биотехнологии, конкретно к получению пегилированного конъюгата варианта рекомбинантного консенсусного интерферона, и может быть использовано в медицине. Изобретение позволяет получить лекарственный препарат против HBV на основе интерферона, в котором активированная молекула ПЭГ через короткий линкер присоединена к α-аминогруппе глицина на N-конце варианта рекомбинантного консенсусного интерферона. Изобретение позволяет получить лекарственный препарат против HBV с повышенной растворимостью в воде и сниженной токсичностью и иммуногенностью по сравнению с природным интерфероном. 2 н. и 1 з.п. ф-лы, 6 ил., 12 пр.
RU2013119183/10A 2010-10-25 2011-03-18 Пегилированный конъюгат варианта рекомбинантного консенсусного интерферона и способ его получения, и применение RU2575796C9 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201010516710.1A CN102453089B (zh) 2010-10-25 2010-10-25 重组集成干扰素变异体聚乙二醇偶联物的制备和应用
CN201010516710.1 2010-10-25
PCT/CN2011/071952 WO2012055205A1 (zh) 2010-10-25 2011-03-18 聚乙二醇化的重组集成干扰素变异体偶联物及其制备方法和应用

Publications (4)

Publication Number Publication Date
RU2013119183A RU2013119183A (ru) 2014-12-10
RU2575796C2 RU2575796C2 (ru) 2016-02-20
RU2575796C1 true RU2575796C1 (ru) 2016-07-20
RU2575796C9 RU2575796C9 (ru) 2016-07-20

Family

ID=

Also Published As

Publication number Publication date
RU2013119183A (ru) 2014-12-10
CN102453089B (zh) 2014-06-04
CN102453089A (zh) 2012-05-16
WO2012055205A1 (zh) 2012-05-03

Similar Documents

Publication Publication Date Title
HRP20191852T1 (hr) Polipeptidi
MX338914B (es) Polipeptidos biosinteticos de espira aleatoria de prolina/alanina y sus usos.
PH12015501092A1 (en) Anti-ceacam5 antibodies and uses thereof
MX336412B (es) Nuevos analogos de glucagon.
MX2012002502A (es) Conjugados de polietilenglicol/peptidos enlazados por disulfuro para la transfeccion de acidos nucleicos.
UA107571C2 (xx) Фармацевтична композиція
NZ604089A (en) Multivalent glycopeptide constructs and uses thereof
NZ601818A (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers
EA201590622A1 (ru) Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
MX2016002152A (es) Metodo para aumentar la expresion de proteinas codificadas por arn.
MX2013011175A (es) Analogos de glucagon novedosos.
RS52115B (en) NEW FORMULATIONS OF TUMOR-ASSOCIATED PEPTIDES BINDING ON HUMAN LEUKOCYTIC ANTIGEN (HLA) CLASS I OR II MOLECULES FOR VACCINES
AR094180A1 (es) Derivados de exendina-4
EA201391756A1 (ru) Композиции, содержащие, способы, включающие, и применение производных доластатина, связанных с неприродными аминокислотами
WO2012112690A3 (en) Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains
EA201201446A1 (ru) Пептидные производные, их получение и применение
UA109949C2 (uk) Композиція і лікарський засіб, які містять ідуронат-2-сульфатазу, і спосіб їх отримання
AR089506A1 (es) Un conjugado de glp-2 especifico del sitio que emplea un fragmento de inmunoglobulina
BR112015010756A8 (pt) vacina de emergência baseada em peptídeo sintético contra doença do pé-e-boca (fmd)
EA201270419A1 (ru) Пролекарства гуанфацина
RU2018120387A (ru) Ангиотензин в лечении состояний головного мозга
EA201490901A1 (ru) Линкеры на основе тирозина для свободного соединения пептидов
JP2014502961A5 (ru)
RU2014122171A (ru) Пептидные аналоги для лечения заболеваний и расстройств
NZ601980A (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same

Legal Events

Date Code Title Description
TH4A Reissue of patent specification
TK4A Correction to the publication in the bulletin (patent)

Free format text: AMENDMENT TO CHAPTER -FG4A- IN JOURNAL: 5-2016 FOR TAG: (72)

PC41 Official registration of the transfer of exclusive right

Effective date: 20160818